Shenyang Xingqi Pharmaceutical Co., Ltd. (300573.SZ) is a high-tech enterprise specializing in the research, development, production, and sale of ophthalmic drugs in China. Founded in 1977 and headquartered in Shenyang, Liaoning Province, the company offers a broad portfolio of eye care products including myopia prevention and control medications such as Xingqi Meoupin atropine sulfate eye drops for delaying myopia progression in children aged 6-12; dry eye treatments like Zirun cyclosporine eye drops, Sugaojie calf blood deproteinized extract eye gel and drops, Ziyang vitamin A palmitate eye gel, Yingrun hydroxypropyl methylcellulose eye drops, Aoshiming and Aierning sodium hyaluronate eye drops; ophthalmic anti-infective drugs such as Dikelo levofloxacin and ofloxacin eye drops and ointment, Dinuo lysostaphin eye drops, Diyou gatifloxacin eye gel; anti-inflammatory products including Difei diclofenac sodium eye drops; mydriatic and cycloplegic agents like Zhuobian compound tropicamide eye drops and Disan atropine sulfate eye gel; miotic and anti-glaucoma drugs; and other offerings such as Shike compound electrolyte intraocular irrigation solution, along with ancillary services in ophthalmology hospitals, optometry, glasses, health foods, and medical devices. The company operates primarily in the People's Republic of China through an extensive distribution network of direct sales and pharmaceutical partnerships, targeting treatments for myopia, dry eye, infections, inflammation, and corneal conditions. In recent developments, Shenyang Xingqi reported strong first-half 2025 revenue growth of 30.4% to RMB 1.163 billion and net profit up 97.8% to RMB 335 million driven by expanded sales of low-concentration atropine products; announced expectations for CNY 850 million in funding as of May 2025; approved a 2024 final cash dividend of 10 yuan per 10 shares payable in May 2025; participated in the 2025 Gusu Dialogue on pharmaceutical packaging innovation in August 2025; and advanced its new drug pipeline while enhancing quality management initiatives including a quality season press release.